Perspective—weight loss, obstructive sleep apnea therapy, or both for cardiometabolic risk in obesity-related obstructive sleep apnea?

The emergence of potent and durable obesity pharmacotherapies has the potential to drastically alter the treatment landscape for comorbid obesity and obstructive sleep apnea. Recent clinical trials examining the impact of weight loss on obstructive sleep apnea have demonstrated marked improvements in both weight and obstructive sleep apnea severity, leading to the first Food and Drug Administration approval of a weight loss medication for obstructive sleep apnea. However, several questions remain unanswered regarding which trial and management strategies will best optimize real-world outcomes for patients with comorbid obesity and obstructive sleep apnea in an equitable manner.